ACTRN12617000642381已完成1 期
An Open-Label Study to Evaluate the Safety and Tolerability of BTX1503 Solution in Healthy Volunteers
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 24
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 Years 至 65 Years（—）
- 性别
- All
入选标准
- 未提供
排除标准
- 未提供
研究者
相似试验
已完成
1 期
Study of BTX 1503 Solution in Patients with Acne VulgarisAcneACTRN12617001127392Botanix Pharmaceuticals Ltd16
进行中（未招募）
不适用
Open-Label Safety Study of MF/F in AsthmaPersistent AsthmaEUCTR2014-004583-38-Outside-EU/EEASchering-Plough Research Institute, a division of Schering Corporation49
进行中（未招募）
1 期
An Open-Label Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir with or without Dasabuvir in Adults with Genotype 1a or Genotype 4 Chronic Hepatitis C Virus (HCV) Infection, with Severe Kidney Impairment or End-Stage Kidney Disease (RUBY-II)EUCTR2015-002012-33-ESAbbVie Deutschland GmbH & Co. KG18
进行中（未招募）
1 期
A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir with Ribavirin in Adults with Genotype 1 and Ombitasvir/Paritabprevir/Ritonavir with Ribavirin in Adults with Genotype 4 Chronic Hepatitis C Virus Infection and Decompensated CirrhosisEUCTR2014-001477-13-DEAbbVie Deutschland GmbH & Co. KG60
已完成
1 期
Topical Hidracare Solution in Participants with Mild to Moderate Hidradenitis SuppurativaHidradenitis suppurativaACTRN12619001734156Aerotech Australia Pty Ltd19